PSTA-6208 / Prospect Therap - LARVOL DELTA

First disclosure of a highly potent and selective oral KRAS G12V inhibitor PSTA-6208 (AACR 2026) - "In head-to-head comparisons, PSTA-6208 was 17-fold more potent than RMC-5127. PSTA-6208 is a potent, highly selective, and orally bioavailable KRAS G12V inhibitor. Its compelling preclinical profile—including sub-nanomolar cellular potency, exceptional selectivity, favorable pharmacokinetics, and robust in vivo efficacy culminating in tumor regression at low doses—strongly supports its further development as a clinical candidate for KRAS G12V-driven cancers."

Oncology • KRAS